Published in Gene Therapy Weekly, May 11th, 2006
Following the landmark approval of Rexin-GTM for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila. Dr. Erlinda Maria Gordon, MD, chairman, said, "We are pleased that the value of Rexin-GTM in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.